RT Journal Article SR Electronic T1 Identification of Multi-repeat Sequences using Genome Mining Approaches for Developing Highly Sensitive Molecular Diagnostic Assay for the Detection of Chlamydia trachomatis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.07.19.22272924 DO 10.1101/2023.07.19.22272924 A1 Shiluli, Clement A1 Kamath, Shwetha A1 Kanoi, Bernard N. A1 Kimani, Rachael A1 Maina, Michael A1 Waweru, Harrison A1 Kamita, Moses A1 Ndirangu, Ibrahim A1 Abkallo, Hussein M. A1 Oduor, Bernard A1 Pamme, Nicole A1 Dupaty, Joshua A1 Klapperich, Catherine M. A1 Lolabattu, Srinivasa Raju A1 Gitaka, Jesse YR 2023 UL http://medrxiv.org/content/early/2023/07/23/2023.07.19.22272924.abstract AB Chlamydia trachomatis (C. trachomatis) is a common sexually transmitted infection (STI). In 2019, the World Health Organization reported about 131 million infections. The majority of infected patients are asymptomatic with cases remaining undetected. It is likely that missed C. trachomatis infections contribute to preventable adverse health outcomes in women and children. Consequently, there is an urgent need of developing efficient diagnostic methods. In this study, genome-mining approaches to identify identical multi-repeat sequences (IMRS) distributed throughout the C. trachomatis genome were used to design a primer pair that would target regions in the genome. Genomic DNA was 10-fold serially diluted (100pg/μL to 1×10-3pg/μL) and used as DNA template for PCR reactions. The gold standard PCR using 16S rRNA primers was also run as a comparative test, and products were resolved on agarose gel. The novel assay, C. trachomatis IMRS-PCR, had an analytical sensitivity of 9.5 fg/μL, representing better sensitivity compared with 16S rRNA PCR (4.31 pg/μL). Our experimental data demonstrate the successful development of lateral flow and isothermal assays for detecting C. trachomatis DNA with potential use in field settings. There is a potential to implement this concept in miniaturized, isothermal, microfluidic platforms, and laboratory-on-a-chip diagnostic devices for reliable point-of-care testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Royal Society, Future Leaders African Independent Researchers (FLAIR) Scheme (FLR\R1\201314) to JGAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Mount Kenya University Ethics Review CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.dropbox.com/s/2lzkgmx10tsfnz5/NG_Data_F.pptx?dl=0